Tempest Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
TPST$0.37+3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-In · Deficit · TotalStockholders' | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Accumulated | Equity (Deficit) | |
| BALANCE — December 31, 2022 | 10,518,539 | $11 | $153,872 | $(135,772) | $18,111 |
| Exercise of stock options | 713 | — | 1 | — | 1 |
| Issuance of common stock for cash, net of issuance cost of $1,105 | 8,323,218 | 8 | 35,590 | — | 35,598 |
| Exercise of pre-funded warrants | 3,202,785 | 3 | — | — | 3 |
| Share-based compensation | — | — | 2,546 | — | 2,546 |
| Net loss | — | — | — | (29,491) | (29,491) |
| BALANCE — December 31, 2023 | 22,045,255 | $22 | $192,009 | $(165,263) | $26,768 |
| Issuance of common stock for cash, net of issuance cost of $1,056 | 21,626,191 | 22 | 28,569 | — | 28,591 |
| Share-based compensation | — | — | 5,303 | — | 5,303 |
| Issuance of common stock under equity plan awards | 300,176 | — | 307 | — | 307 |
| Net loss | — | — | — | (41,843) | (41,843) |
| BALANCE — December 31, 2024 | 43,971,622 | $44 | $226,188 | $(207,106) | $19,126 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.